Proteros applied its industrial structural biology platform and proprietary technologies to deliver protein ligand structures to Almirall Scientists for a known, extremely challenging protein where little published data is available, particularly on solving specific protein ligand structures.
Proteros delivered the solved structures within the timeframes agreed at the beginning of the collaboration.
Torsten Neuefeind, CEO of proteros, said: “we are pleased that Proteros’s approach to structural biology, of applying our unique technologies in an industrial process, has proven to offer an effective and valuable service to our client’s scientists allowing them to make early decision on their drug discovery programs.”